SecBot SecBot

PALI

PALISADE BIO, INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001357459 Biotech & Drug Discovery
$1.03 −0.09 (−8.04%)
Nov 16 4:00 PM ET · prev $1.12
Market cap
$204.4M
Micro cap
Consensus
Buy
94% Buy or better · 17 analysts
Median target
$7.50
+628% · range $5.00–16.00
1 year
−50.2%
from $2.07 · Nov 17
30 days
−23.1%
from $1.34
52-week range
$1.03–2.80
at the low
Avg volume 20D
3.73M
Nov 3 spike 18.64M
Short interest
29.29M
≈16.8% of shares · −7.7%
Days to cover
7.8
at average volume
Insider net
−$141.2K
2 buyers · 2 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read MIXED 6 reports · 90 days
Balance 0 bearish · 1 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 3/6

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    2 insiders bought $279.0K at an average $1.92. 2 insiders sold $420.2K. Price is 46% below their cost.

  • InstitutionsBULLISH

    Q3 2026: 16 added (0 new), 9 trimmed or exited.

  • AnalystsBULLISH

    16 of 17 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.061 → −$0.061 over 90 days. 2 up, 4 down in 30 days.

  • Short sellersSTEADY

    Short interest −7.7% to 29.29M shares. 7.8 days to cover, ≈16.8% of shares.

  • TrendDOWNTREND

    29% below its 50-day average. New closing low $1.03 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED7,888,020$10.6M
LOS ANGELES CAPITAL MANAGEMENT LLCDOUBLED2,130,631$2.9M
VANGUARD PORTFOLIO MANAGEMENT LLCADD1,442,126$1.9M
VANGUARD FIDUCIARY TRUST COADD1,117,461$1.5M
UBS Group AGADD1,078,227$1.5M
Aberdeen Group plcNEAR_EXIT80,233$1.2M
Nuveen, LLCTRIM524,637$708.3K
AMERICAN CENTURY COMPANIES INCADD205,883$277.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 94% rate it Buy or better
Strong Buy6Buy10Hold1Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +628%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 11, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Nov 11, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 13, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Oct 9, 2026Raymond James
INITIATE
INITIATEOutperform
Sep 23, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jul 23, 2026Oppenheimer
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$279.0K
bought · 2 insiders
$420.2K
sold · 2 insiders
−46.5%
vs their $1.92 cost
DateInsiderTypeValue
Oct 19, 2026
Capers Julien E.
See Remarks
Oct 19, 2026
AWARD787,300 sh
Oct 6, 2026
Jones Mitchell Lawrence
See Remarks
Oct 6, 2026
EXERCISE2,620,850 sh
Oct 6, 2026
Finley John David
CEO CFO
Oct 6, 2026
EXERCISE3,059,800 sh
Oct 6, 2026
Finley John David
CEO CFO
Oct 6, 2026
TAX W/H$2.1M
Oct 6, 2026
Jones Mitchell Lawrence
See Remarks
Oct 6, 2026
EXERCISE2,555,266 sh
Oct 6, 2026
Finley John David
CEO CFO
Oct 6, 2026
EXERCISE3,227,384 sh
Oct 6, 2026
Jones Mitchell Lawrence
See Remarks
Oct 6, 2026
EXERCISE65,584 sh
Oct 6, 2026
Finley John David
CEO CFO
Oct 6, 2026
EXERCISE167,584 sh

Earnings setup

Estimates
−$0.06
EPS estimate, this quarter
+0%
estimate change, 90 days
2↑ 4↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.06-$0.07–-$0.05+0.3%$0.00
Next Q-$0.08-$0.08–-$0.08-20.0%$0.00
Current FY🔒 Fresh data, subscribers only
Next FY-$0.33-$0.41–-$0.29-16.7%$0.00

Short side

FINRA· Oct 30, 2026
29,290,111
shares short
-7.7%
vs prior settlement
7.8
days to cover
≈16.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 10, 2026 Earnings
Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs
First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027
Nov 10, 2026 SEC
Palisade Bio reported Q3 2026 net loss of $14.6M ($0.07 per share), wider than the $2.9M loss a year ago, as R&D…
8-K · Impact 5/10
Nov 9, 2026 SEC
Soleus Capital Master Fund, L.P. filed an amended Schedule 13G disclosing a 8.6% passive stake in Palisade Bio, Inc…
SC 13G/A · Impact 3/10
Oct 19, 2026 Insider
Capers Julien E. was granted 787,300 shares
See Remarks
Oct 6, 2026 Insider
Jones Mitchell Lawrence acquired via exercise 2,620,850 shares
See Remarks
Oct 6, 2026 Insider
Finley John David acquired via exercise 3,059,800 shares
CEO CFO
Sep 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC · DOUBLED
7,888,020 shares ($10.6M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 10, 2026
Earnings
Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs
First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027
Nov 9, 2026
Earnings date
PALI Q3 2026 Earnings Scheduled · 2026-11-09
Oct 28, 2026
Press release
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory…
Sep 28, 2026
Press release
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn’s disease
Sep 23, 2026
Press release
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108

SecBot reports

13 filings · 1 press release · 0 bullish · 0 bearish · 1 mixed · 12 neutral
All PALI filing & press-release reports (14)